ATLANTA, GA – – (ACCESSWIRE – January 5, 2023) – – Holzer & Holzer, LLC informs investors that a class action lawsuit has been filed against BioLineRx Ltd. (“BioLineRx” or the “Company”) (NASDAQ: BLRX). The lawsuit alleges BioLineRx made materially false and misleading statements and/or failed to disclose material adverse facts about the Company’s business, operations, and prospects, including: (1) the Company was not well enough financed to develop its drug candidate, Motixafortide, while at the same time advancing other pipeline programs; and (2) BioLineRx would require a loan from Kreos Capital VII Aggregator SCSP in an aggregate principal amount of up to $40 million and then also would require a $15M securities offering to facilitate the commercial launch of Motixafortide.
If you bought shares of BioLineRx between February 23, 2021 and September 19, 2022, and you suffered a significant loss on that investment, you are encouraged to discuss your legal rights by contacting Corey Holzer, Esq. at email@example.com or Joshua Karr, Esq. at firstname.lastname@example.org, by toll-free telephone at (888) 508-6832 or you may visit the firm’s website at https://holzerlaw.com/case/biolinerx/ to learn more.
The deadline to ask the court to be appointed lead plaintiff in the case is March 6, 2023.
Lead Plaintiff Deadline Has Passed
March 6, 2023